Massachusetts Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.03M Sell
9,350
-115
-1% -$25.5K 0.88% 47
2025
Q4
$2.16M Sell
9,465
-41
-0.4% -$9.34K 1.01% 42
2025
Q3
$2.2M Sell
9,506
-150
-2% -$30.5K 1.09% 37
2025
Q2
$1.79M Sell
9,656
-175
-2% -$32.5K 1.01% 41
2025
Q1
$2.06M Sell
9,831
-135
-1% -$26.2K 1.41% 31
2024
Q4
$1.77M Sell
9,966
-50
-0.5% -$9.19K 1.09% 44
2024
Q3
$1.98M Sell
10,016
-125
-1% -$23.3K 1.25% 38
2024
Q2
$1.74M Sell
10,141
-125
-1% -$20.7K 1.17% 37
2024
Q1
$1.87M Sell
10,266
-200
-2% -$34.5K 1.32% 31
2023
Q4
$1.62M Sell
10,466
-159
-1% -$23.2K 1.31% 30
2023
Q3
$1.58M Sell
10,625
-125
-1% -$18.4K 1.45% 23
2023
Q2
$1.45M Sell
10,750
-75
-0.7% -$11K 1.39% 28
2023
Q1
$1.73M Sell
10,825
-625
-5% -$95.6K 1.78% 18
2022
Q4
$1.69M Buy
+11,450
New +$1.76M 1.63% 21

Other funds holding ABBV

Massachusetts Wealth Management's ABBV Position: Q1 2026 in Review

Massachusetts Wealth Management reduced its AbbVie (ABBV) stake by 1.2% in Q1 2026, selling an estimated $25.5K and leaving 9,350 shares worth $2.03M. The position accounts for 0.88% of the portfolio, ranked #47.

Massachusetts Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.2M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Massachusetts Wealth Management held 9,350 shares of AbbVie worth $2.03M as of Q1 2026.
  • Massachusetts Wealth Management sold 115 AbbVie shares in Q1 2026, an estimated $25.5K.
  • AbbVie made up 0.88% of Massachusetts Wealth Management's portfolio in Q1 2026, its #47 holding.
  • Massachusetts Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Massachusetts Wealth Management's AbbVie position peaked at $2.2M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Massachusetts Wealth Management's 13F filing for Q1 2026, filed 15 Apr 2026.